Bulletin from Annual General Meeting of Diamyd Medical AB
The following items were addressed at the Annual General Meeting of Diamyd Medical AB (publ) held today:
Diamyd Medical's President and CEO Peter Zerhouni gave a retrospective view of the past year and summarized the most significant events that took place during the fiscal year and after year-end.
The Company's income statement and balance sheet were adopted and the Board members and the Chief Executive Officer were discharged from liability for the 2013/2014 fiscal year. The Annual General Meeting approved the Board's proposal that no dividend be paid for the 2013/2014 fiscal year.
Anders Essen-Möller was re-elected as Chairman of the Board and Maria-Teresa Essen-Möller and Erik Nerpin were re-elected to the Board. Fredrik Åhlander was elected as new Board member. Fredrik Åhlander, born in 1973, is an MD and biologist with degrees from Lund University. He works as a physician and conducts clinical research.
The Annual General Meeting approved the proposed remuneration to Board members and the Chairman of the Board.
The Annual General Meeting resolved to elect the auditing company BDO until the end of the Annual General Meeting 2015. Principal auditor is the authorized public accountant Johan Pharmanson.
The AGM resolved to authorize the Board, on one or more occasions prior to the next Annual General Meeting to issue shares and to deviate from the shareholders' preferential rights when so doing. Payment may be made in cash, through a contribution or by offsetting. In a share issue for cash payment and in deviation from the shareholders' preferential rights, the number of shares issued pursuant to the authorization may not exceed 20 percent of the shares in the Company when the share issue occurs.
About Diamyd Medical
Diamyd Medical is dedicated to fighting type 1 diabetes and to working toward a cure for the disease. Diamyd Medical’s projects include development of combination regimens with the GAD-based diabetes vaccine Diamyd® for arresting the successive destruction of insulin-producing beta cells. Diamyd Medical licenses exclusive intellectual rights for the GAD molecule from the University of California. The company also has an exclusive license from the University of California for therapeutic use of GABA for the treatment of diabetes and other inflammation-related conditions, including metabolic syndrome and rheumatoid arthritis.
Diamyd Medical owns 46 percent of the stem cell company Cellaviva AB, which is establishing a Swedish commercial bank for private family saving of stem cells in umbilical cord blood and other sources of stem cells. Stem cells are expected to be used in Personalized Regenerative Medicine (PRM), for example, to restore beta cell mass in diabetes patients where autoimmunity has been arrested. Diamyd Medical also has a 10 percent shareholding in the medical technology company Companion Medical, Inc., based in San Diego, in the US, and a minor shareholding and other financial interests in the US gene therapy company Periphagen Holdings, Inc.
Remium Nordic AB is the Company’s Certified Adviser.
For further information, please contact:
Anders Essen-Möller, Chairman Diamyd Medical AB
Phone: +46 70 55 10 679. E-mail: anders.essen-moller@diamyd.com
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.
Tags: